Attached files
| file | filename |
|---|---|
| 8-K - FORM 8-K - ImmunoCellular Therapeutics, Ltd. | rrd393621.htm |
| EX-99 - PRESS RELEASE DATED NOVEMBER 6, 2013 - ImmunoCellular Therapeutics, Ltd. | rrd393621_40168.htm |
| Condensed Balance Sheets | ||||||||||||||||
| 9/30/2013 | 12/31/2012 | |||||||||||||||
| (unaudited) | ||||||||||||||||
|
|
|
|
|
|||||||||||||
| Cash | $ | 29,433,560 | $ | 26,216,668 | ||||||||||||
| Other current assets | 401,962 | 714,508 | ||||||||||||||
| Non current assets | 103,511 | 88,025 | ||||||||||||||
|
|
|
|
|
|||||||||||||
| $ | 29,939,033 | $ | 27,019,201 | |||||||||||||
|
|
|
|
|
|||||||||||||
| Current liabilities | $ | 1,067,529 | $ | 1,098,307 | ||||||||||||
| Warrant liabilities | 3,690,609 | 2,852,880 | ||||||||||||||
| Shareholders' equity | 25,180,895 | 23,068,014 | ||||||||||||||
|
|
|
|
|
|||||||||||||
| $ | 29,939,033 | $ | 27,019,201 | |||||||||||||
|
|
|
|
|
|||||||||||||
| Condensed Statement of Operations (Unaudited) | ||||||||||||||||
| 3 months | 3 months | 9 months | 9 months | |||||||||||||
| ended | ended | ended | ended | |||||||||||||
| 9/30/2013 | 9/30/2012 | 9/30/2013 | 9/30/2012 | |||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Revenue | $ | - | $ | - | $ | - | $ | - | ||||||||
| Research and development | 1,276,507 | 2,378,917 | 3,905,338 | 6,567,086 | ||||||||||||
| Stock based compensation | 156,277 | 33,887 | 500,351 | 382,611 | ||||||||||||
| General and administrative | 985,107 | 1,004,181 | 2,542,794 | 2,647,301 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Loss before other expenses | (2,417,891) | (3,416,985) | (6,948,483) | (9,596,998) | ||||||||||||
| Interest income | 3,667 | 1,858 | 14,310 | 4,867 | ||||||||||||
| Financing expense | - | - | - | (368,524) | ||||||||||||
| Change in fair value of warrant liabilities | (1,379,217) | 2,777,500 | (1,983,388) | (5,018,224) | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Net loss | $ | (3,793,441) | $ | (637,627) | $ | (8,917,561) | $ | (14,978,879) | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||